BUY Divi's Laboratories Limited — Rajesh Palviya, Axis Securities
byRajesh Palviya, Axis SecuritiesHorizon: NA (inferred Swing (≤2wk))20 Aug 2026via NDTV Profit
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
2 advisors have active intraday BUY calls on this stock, all issued in the last 14 days
Advisor consensus · adjacent horizon·25 Aug · today
1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·26 Aug · today
1500% Dividend Bonanza! Pharma Stock In Spotlight After Mega Payout; Record Date Announced
NewsGoogle News·19 Aug · 6d ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Divi's Laboratories
- BUY — Ashish Bahety, Profitmart Securities22 Oct 2026 · Same day · target ₹9,350 · SL hit
- SELL — Prakash Gaba14 Oct 2026 · ~2 weeks · target ₹8,750 · SL hit
- SELL — Mehul Kothari, Anand Rathi14 Oct 2026 · ~2 weeks · target ₹8,400 · Active
- BUY — Kavita Jain, Arihant Capital Markets6 Oct 2026 · Next day · target ₹9,750 · Expired
- BUY — Chandan Taparia, Motilal Oswal24 Sept 2026 · ~2 weeks · target ₹10,000 · SL hit
More from Rajesh Palviya, Axis Securities
- BUY Sansera Engineering8 Oct 2026 · ~2 weeks · target ₹4,350 · SL hit
- BUY Trent8 Oct 2026 · ~2 weeks · target ₹3,050 · SL hit
- SELL Sun Pharmaceutical Industries5 Oct 2026 · ~3 months · target ₹1,720 · SL hit
- BUY Cipla29 Sept 2026 · ~2 weeks · target ₹1,480 · SL hit
- BUY Zydus Lifesciences29 Sept 2026 · ~2 weeks · target ₹1,280 · SL hit